Diamyd Medical Ab Stock Fundamentals
| DMYD-B Stock | SEK 13.60 0.62 4.78% |
Diamyd Medical AB fundamentals help investors to digest information that contributes to Diamyd Medical's financial success or failures. It also enables traders to predict the movement of Diamyd Stock. The fundamental analysis module provides a way to measure Diamyd Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diamyd Medical stock.
Diamyd |
Diamyd Medical AB Company Current Valuation Analysis
Diamyd Medical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Diamyd Medical Current Valuation | 1.06 B |
Most of Diamyd Medical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diamyd Medical AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Diamyd Medical AB has a Current Valuation of 1.06 B. This is 92.65% lower than that of the Healthcare sector and 77.27% lower than that of the Biotechnology industry. The current valuation for all Sweden stocks is 93.65% higher than that of the company.
Diamyd Medical AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Diamyd Medical's current stock value. Our valuation model uses many indicators to compare Diamyd Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Diamyd Medical competition to find correlations between indicators driving Diamyd Medical's intrinsic value. More Info.Diamyd Medical AB is rated # 3 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Diamyd Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Diamyd Medical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Diamyd Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diamyd Medical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diamyd Medical could also be used in its relative valuation, which is a method of valuing Diamyd Medical by comparing valuation metrics of similar companies.Diamyd Medical is currently under evaluation in current valuation category among its peers.
Diamyd Fundamentals
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (170.83) % | |||
| Current Valuation | 1.06 B | |||
| Shares Outstanding | 76.93 M | |||
| Shares Owned By Insiders | 35.22 % | |||
| Shares Owned By Institutions | 0.26 % | |||
| Price To Earning | (4.21) X | |||
| Price To Book | 5.67 X | |||
| Price To Sales | 2,531 X | |||
| Revenue | 454 K | |||
| Gross Profit | (3.95 M) | |||
| EBITDA | (98.88 M) | |||
| Net Income | (118.18 M) | |||
| Cash And Equivalents | 119.76 M | |||
| Cash Per Share | 1.02 X | |||
| Current Ratio | 5.83 X | |||
| Book Value Per Share | 2.36 X | |||
| Cash Flow From Operations | (93.22 M) | |||
| Earnings Per Share | (1.45) X | |||
| Number Of Employees | 20 | |||
| Beta | 1.91 | |||
| Market Capitalization | 1.21 B | |||
| Total Asset | 236.52 M | |||
| Retained Earnings | (31 M) | |||
| Working Capital | 28 M | |||
| Current Asset | 33 M | |||
| Current Liabilities | 5 M | |||
| Net Asset | 236.52 M |
About Diamyd Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diamyd Medical AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diamyd Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diamyd Medical AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. Diamyd Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.